Drug Classes · Complete Reference 2026

GLP-1 Receptor Agonists —
Drug Classes & Pipeline

The most comprehensive classification of GLP-1 receptor agonists available — from first-generation exendin-4 analogues through to next-generation triple agonists, oral small-molecule agents, and investigational compounds entering trials through 2030. Each entry covers structural pharmacology, licensed indications, pivotal trial data, and UK prescribing status.

S.K.H. Kazmi
Updated July 2026
NICE NG28 · SfE · ADA 2025
Pipeline through 2030
Overview

Drug Class Taxonomy

Structural classification and therapeutic positioning

GLP-1 receptor agonists are classified by their structural origin, half-life strategy, and receptor selectivity. The field has evolved from simple peptide analogues of native GLP-1 to sophisticated multi-receptor co-agonists and, most recently, oral non-peptide small molecules — a trajectory from parenteral peptides to daily oral tablets that mirrors the historical arc of insulin therapy.

The classification used here distinguishes seven generations based on primary pharmacological innovation:

I
Exendin-4 analogues — Short-acting, non-human peptide
Exenatide IR · Lixisenatide · Derived from Gila monster venom peptide · 53% GLP-1 homology
2
Licensed UK
II
Fatty acid–acylated GLP-1 analogues — Once daily
Liraglutide · ≥94% GLP-1 homology · Albumin-binding via palmitoyl chain · 13 h half-life
1
Licensed UK
III
Ultra-long-acting peptides — Once weekly
Semaglutide · Dulaglutide · Efpeglenatide · Fatty diacid or Fc-fusion strategies · 5–7 day t½
3
Licensed UK
IV
Dual GIP/GLP-1 co-agonists — Comparative weight-management evidence
Tirzepatide · Full GIPR + partial GLP-1R agonism · Once weekly · Up to 22.5% weight loss
1
Licensed UK
V
Triple agonists — GIP + GLP-1 + Glucagon receptor
Retatrutide · Mazdutide · Phase 3 · Targets energy expenditure via glucagon receptor in addition to dual agonism
2+
Phase 3
VI
Oral small-molecule GLP-1 RAs — Non-peptide
Orforglipron · Danuglipron · Lotiglipron · Once-daily tablets · No SNAC absorption enhancer required
3+
Phase 3
VII
Novel co-agonist & combination strategies — 2027–2030
GLP-1/amylin · GLP-1/FGF21 · GLP-1/GCG · Brain-biased variants · Monthly / implant delivery
8+
Phase 1–3
Timeline

Regulatory Approval History

FDA and EMA approvals 2005–2026 and projected beyond

2005 · FDA
Exenatide (Byetta)
First GLP-1 RA approved · T2DM · Twice daily SC · Amylin/Eli Lilly
2010 · FDA / EMA
Liraglutide (Victoza)
First once-daily GLP-1 RA · T2DM · Novo Nordisk · Later approved Saxenda 2014 (obesity)
2012 · FDA / EMA
Exenatide XR (Bydureon) & Lixisenatide (Lyxumia)
First once-weekly GLP-1 RA (Bydureon) · Lixisenatide — strong postprandial effect, low CV data
2014–2017 · FDA / EMA
Albiglutide (Tanzeum) · Dulaglutide (Trulicity) · Semaglutide SC (Ozempic)
Albiglutide: Fc-fusion, later withdrawn commercially 2018 · Dulaglutide: pen device · Semaglutide: highest efficacy peptide of its era
2019 · FDA
Oral Semaglutide (Rybelsus)
First oral GLP-1 RA · SNAC absorption enhancer · T2DM · EMA 2020 · NICE approval 2022
2021 · FDA · EMA 2022
Semaglutide 2.4 mg (Wegovy)
Obesity indication · STEP programme · 15% mean weight loss · NICE approval 2023
2022 · FDA · UK weight management 2023
Tirzepatide (Mounjaro; Zepbound is US branding)
First dual GIP/GLP-1 RA · UK-authorised for T2DM and weight management · NICE TA1026 / NG28
Development pipeline · verify current status
Retatrutide · Orforglipron · CagriSema
Triple agonist (Retatrutide) · oral non-peptide (Orforglipron) · GLP-1/amylin (CagriSema) · not presented as authorised therapy
2027–2030 · Projected
Monthly / implant · GLP-1/FGF21 · Brain-biased agents
Ultra-long-acting formulations · Subcutaneous implants · Tissue-specific GLP-1 agonism · Combination pharmacology with SGLT2i
Generation I

Exendin-4 Analogues

Short-acting · Non-human peptide origin · 53% GLP-1 homology

The first generation of GLP-1 RAs is structurally derived from exendin-4, a 39-amino-acid peptide isolated from the venom of the Gila monster (Heloderma suspectum). Despite only 53% sequence identity with human GLP-1, exendin-4 binds and activates the human GLP-1 receptor with high affinity — and crucially, its position-2 glycine substitution (vs alanine in GLP-1) confers complete resistance to DPP-4 cleavage. This provided the structural proof of concept that a non-human peptide could form the basis of effective GLP-1R agonist therapy.

💉
Exenatide
Byetta (IR) · Bydureon / Bydureon BCise (XR) · Eli Lilly / AstraZeneca
✓ UK Licensed Generation I T2DM
Origin
Exendin-4 (Gila monster)
GLP-1 Homology
53% sequence identity
IR half-life
~2.4 hours
XR half-life
~2 weeks (PLGA depot)
IR dosing
5–10 mcg SC twice daily
XR dosing
2 mg SC once weekly
Elimination
Renal (proteolysis)
eGFR cutoff
Avoid if <45 mL/min
Structural Pharmacology
Exenatide is a synthetic replicate of exendin-4. Its Gly² substitution prevents DPP-4 cleavage at the His-Gly bond. The XR formulation (Bydureon) encapsulates exenatide in poly(lactic-co-glycolic acid) (PLGA) microspheres — a biodegradable polymer matrix that releases the peptide over approximately 10 weeks as polymer hydrolysis progresses. This delivery system achieves once-weekly dosing purely through sustained subcutaneous release, not through modification of the peptide's pharmacokinetics. The microspheres produce a visible subcutaneous nodule at injection sites in some patients.
Clinical Profile
As a short-acting agent, exenatide IR primarily suppresses postprandial glucose through gastric emptying delay and meal-related insulin stimulation, with comparatively modest effects on fasting glucose. This differentiates it mechanistically from once-weekly agents: short-acting GLP-1 RAs produce greater meal-related GLP-1R agonism (relevant for postprandial hyperglycaemia) but less continuous receptor occupancy (less fasting glucose control). Exenatide IR must be administered within 60 minutes before the two main meals of the day — a prescribing detail with significant adherence implications.
Key Trial Evidence
DURATION-1
HbA1c −1.9% (XR vs IR)
XR superior to IR · 26 weeks
EXSCEL
MACE neutral (HR 0.91)
CV safety · n=14,752 · 2017
HbA1c reduction
−0.8 to −1.5%
Dose-dependent · vs baseline
Limitations & Current Use
Exenatide has been largely superseded by semaglutide and tirzepatide for new prescriptions in T2DM management, given inferior HbA1c reduction, weight loss, and CV outcome data. EXSCEL demonstrated CV safety (non-inferiority) but not superiority, unlike LEADER (liraglutide), SUSTAIN-6 (semaglutide), and SELECT (semaglutide). Current use is primarily in patients with established exenatide tolerance who are maintained on therapy, or where cost is the primary driver. Renal impairment is a significant limitation — exenatide requires GFR ≥45 mL/min and is contraindicated in severe renal impairment, unlike semaglutide which can be used at any eGFR (though with caution).
Licensed UK — T2DM (IR & XR) NICE: 2nd/3rd line · Not preferred vs semaglutide · EXSCEL safety data
💉
Lixisenatide
Lyxumia (monotherapy) · Suliqua (fixed-ratio with insulin glargine) · Sanofi
✓ UK Licensed Generation I T2DM Postprandial specialist
Origin
Exendin-4 + C-terminal Lys×6
Half-life
~3 hours
Dosing
10–20 mcg SC once daily
Special feature
Strongest gastric emptying delay
Structural Pharmacology
Lixisenatide is a modified exendin-4 analogue with six lysine residues appended to the C-terminus and deletion of Pro38. These modifications increase receptor binding affinity and confer additional DPP-4 resistance while extending the half-life modestly to ~3 hours. Among all GLP-1 RAs, lixisenatide produces the most pronounced gastric emptying delay, resulting in a disproportionately large postprandial glucose-lowering effect relative to its overall HbA1c reduction — making it uniquely suited to patients with isolated postprandial hyperglycaemia and predominantly normal fasting glucose.
CV Outcomes — ELIXA Trial
ELIXA (2015, n=6,068) was the first GLP-1 RA cardiovascular outcomes trial. It enrolled patients with T2DM following a recent acute coronary syndrome — a uniquely high-risk population. Lixisenatide demonstrated CV safety (non-inferiority for MACE) but did not demonstrate superiority (HR 1.02, 95% CI 0.89–1.17). Unlike subsequent trials, ELIXA showed no benefit in heart failure hospitalisation and no renal benefit. This trial positioned lixisenatide as the GLP-1 RA with the weakest CV outcomes evidence of the class — though it established the foundational safety dataset that encouraged subsequent trials.
ELIXA
MACE neutral (HR 1.02)
Post-ACS population · n=6,068
Postprandial BG
Largest PPG reduction
Greatest gastric delay of class
Licensed UK — T2DM (standalone & in Suliqua) NICE: Lyxumia standalone rarely used · Suliqua reviewed per NG28
⚠
Generation I — Key Clinical Limitation
Short-acting GLP-1 RAs (exenatide IR, lixisenatide) produce tachyphylaxis of the gastric emptying delay with continuous exposure — an effect that paradoxically limits their long-term postprandial efficacy while short-acting agents maintain it acutely. This is in contrast to once-weekly agents where continuous receptor occupancy produces sustained, if attenuated, gastric motility effects. For most patients with T2DM requiring a GLP-1 RA, once-weekly semaglutide is preferred by NICE NG28 (February 2026) based on superior HbA1c reduction, weight loss, and cardiovascular outcome data.
Generation II

Fatty Acid–Acylated Analogues

Once daily · ≥94% GLP-1 homology · Albumin-binding strategy

The second generation introduced the pivotal innovation of fatty acid acylation to achieve extended plasma half-life through non-covalent albumin binding. Rather than relying on non-human peptide sequences for DPP-4 resistance, these agents are near-identical to human GLP-1 but modified at strategic positions to resist degradation and bind plasma albumin, dramatically extending circulating half-life.

🔵
Liraglutide
Victoza (T2DM 1.2–1.8 mg) · Saxenda (obesity 3.0 mg) · Novo Nordisk
✓ UK Licensed Generation II T2DM + Obesity CV Proven — LEADER
GLP-1 Homology
97% sequence identity
Key modification
C16 palmitoyl at Lys²⁶
Half-life
~13 hours
Albumin binding
>98% (non-covalent)
T2DM dosing
0.6→1.2→1.8 mg SC OD
Obesity dosing
0.6→3.0 mg SC OD (titrate over 5 weeks)
Renal use
Caution eGFR <15; avoid ESRD
HbA1c reduction
~1.0–1.6%
Structural Pharmacology
Liraglutide achieves a 97% homology to native GLP-1 with two modifications: (1) Arg³⁴Lys substitution prevents trypsin cleavage; (2) a C16 palmitoyl fatty acid is attached via a glutamate spacer to Lys²⁶. The palmitoyl chain mediates reversible, non-covalent albumin binding, creating a large effective molecular complex (~70 kDa) that resists renal filtration and protects the peptide from proteolytic degradation. Self-association into heptameric complexes at the SC injection site provides an additional absorption depot, contributing to the ~13-hour half-life and allowing once-daily dosing without loss of glycaemic control during the 12–24-hour inter-dose interval.
LEADER Trial — Landmark CV Evidence
The LEADER trial (2016, NEJM, n=9,340) established liraglutide as the first GLP-1 RA to demonstrate cardiovascular superiority over placebo (standard of care). Primary MACE (CV death, non-fatal MI, non-fatal stroke) was reduced by 13% (HR 0.87, 95% CI 0.78–0.97, p=0.01 for superiority). CV death was specifically reduced by 22% (HR 0.78). All-cause mortality was reduced by 15%. The renal composite outcome was reduced by 22%. LEADER enrolled patients with T2DM at high CV risk (established CVD or ≥1 CV risk factor aged ≥50 years) over a median 3.8 years — and remains the foundational dataset supporting liraglutide's cardiovascular positioning in international guidelines.
Obesity Indication — Saxenda (3.0 mg)
At the higher obesity dose (Saxenda, 3.0 mg OD), liraglutide produces approximately 7–8% mean body weight loss (−8.4 kg absolute; net placebo-adjusted ~5.6%) in clinical trials (SCALE programme), with ~63% of patients achieving ≥5% weight loss at 56 weeks. The SCALE Outcomes trial (n=3,731) demonstrated modest CV risk factor improvement without a powered CV endpoint. Saxenda has been largely superseded in obesity management by semaglutide 2.4 mg (Wegovy) and tirzepatide (Zepbound), which produce 2–4× greater weight loss — though liraglutide remains a NICE-approved option in England under the NHS England Tier 3 specialist weight management service criteria.
LEADER
MACE −13% (HR 0.87)
CV superiority · n=9,340 · 2016
SCALE Obesity
Weight loss −8.4 kg
vs −2.8 kg placebo · 56 weeks
LIRA-RENAL
Safe eGFR 15–59
No dose adjustment needed
Licensed UK — T2DM (Victoza) · Obesity (Saxenda, NHS Tier 3) NICE NG28: semaglutide preferred for most · LEADER CV evidence · CV death reduction
Generation III

Ultra-Long-Acting Once-Weekly Agents

Semaglutide · Dulaglutide · Efpeglenatide · Fatty diacid or Fc-fusion strategies

Generation III agents achieve once-weekly dosing through structural innovations that extend half-life to 5–7 days. Two distinct strategies are employed: enhanced fatty acid acylation (semaglutide: C18 fatty diacid with PEG spacer, achieving stronger albumin binding than liraglutide's C16 chain) and Fc-fusion protein technology (dulaglutide: IgG4 Fc domain linked to two GLP-1 peptides, leveraging FcRn recycling). This generation represents the current standard of care for GLP-1 RA therapy in type 2 diabetes and obesity.

⭐
Semaglutide
Ozempic (SC · T2DM) · Wegovy (SC and oral tablet · weight management) · Rybelsus (oral · T2DM)
✓ UK Licensed — all 3 formulations Generation III — indication-specific roles SELECT CV Superiority 2023 ✓ MASH Approved August 2025
GLP-1 Homology
94% sequence identity
Modification
Aib⁸ + C18 fatty diacid (mini-PEG)
SC half-life
~7 days (165–184 h)
Albumin binding
>99% · 3–4× stronger than liraglutide
Ozempic dosing
0.25→0.5→1→2 mg SC weekly
Wegovy dosing
0.25→2.4 mg SC weekly (5 steps)
Rybelsus
3→7→14 mg oral OD (fasting)
HbA1c reduction
Up to −1.8% (1 mg SC)
Semaglutide Structure and Pharmacology
Semaglutide differs structurally from liraglutide through: (1) Aib⁸ (α-aminoisobutyric acid) at position 8, which reduces DPP-4 cleavage; (2) a C18 fatty diacid attached through a spacer to Lys²⁶, supporting albumin binding; and (3) an Arg³⁴Lys substitution. These features support high protein binding and once-weekly subcutaneous dosing. Comparative efficacy depends on indication, dose, comparator and population and should not be inferred from structural pharmacology alone.
Oral Semaglutide — Indication and Brand Matter
Rybelsus is oral semaglutide authorised for T2DM. A separate Wegovy tablet for weight management was authorised by the MHRA on 11 June 2026 at a different dose schedule (1.5→4→9→25 mg once daily) and is not currently available through the NHS. These products and doses must not be interchanged. Both use an absorption-enhancing oral formulation and require fasting administration; follow the current product information.
SELECT Trial — CV Outcomes Without Diabetes (2023)
The SELECT trial (NEJM 2023, Lincoff et al., n=17,604) was transformative: it enrolled adults with obesity (BMI ≥27) and established cardiovascular disease but without diabetes — demonstrating for the first time that a GLP-1 RA reduces MACE in a non-diabetic population. Semaglutide 2.4 mg SC weekly reduced the primary composite (CV death, non-fatal MI, non-fatal stroke) by 20% (HR 0.80, 95% CI 0.72–0.90, p<0.001) over a mean 39.8 months. This was accompanied by 9.4% weight loss vs 0.9% placebo. SELECT positioned semaglutide as a cardioprotective agent beyond glycaemic control, and its data underpins MHRA and NICE expansion of the obesity indication in 2024–2025.
FLOW Trial — Renal Outcomes (2024)
FLOW (NEJM 2024, n=3,533) was the first dedicated renal outcomes trial for a GLP-1 RA, enrolling patients with T2DM and chronic kidney disease (eGFR 25–75, UACR ≥100). Semaglutide 1 mg SC weekly reduced the kidney-specific composite (sustained ≥50% eGFR decline, ESRD, renal death, CV death) by 24% (HR 0.76, 95% CI 0.66–0.88, p=0.0003). All-cause mortality was reduced by 20%. The trial was stopped early for overwhelming efficacy — and positions semaglutide as a renoprotective agent alongside SGLT2 inhibitors in CKD with T2DM.
MASH — FDA Approved August 2025
The ESSENCE trial demonstrated semaglutide resolved non-cirrhotic MASH (metabolic dysfunction-associated steatohepatitis) with moderate-to-advanced fibrosis (F2-F3) in 62.9% of participants at 72 weeks vs placebo. FDA granted approval for MASH indication in August 2025, making semaglutide the second pharmacotherapy approved for MASH alongside resmetirom (Rezdiffra, thyroid hormone receptor-beta agonist). This expands semaglutide's indication set from metabolic/cardiovascular to hepatic disease, reflecting the interconnected pathophysiology of obesity, T2DM, and MASLD/MASH. Combined with weight loss and CV benefits, semaglutide offers comprehensive cardiometabolic-hepatic protection in a single agent.
Oral Semaglutide 25 mg for Weight Loss — Approved January 2026
FDA approved the first oral GLP-1 receptor agonist for weight loss and major adverse cardiovascular events (MACE) reduction in January 2026. The OASIS 4 trial demonstrated oral semaglutide 25 mg delivered 13.6% mean weight loss in patients with obesity without diabetes — establishing oral delivery as a viable alternative to weekly injections for obesity pharmacotherapy. This approval significantly expands patient access by offering a convenient oral option with proven CV benefit.
SUSTAIN-6
MACE −26% (HR 0.74)
T2DM + high CV risk · n=3,297
SELECT 2023
MACE −20% (HR 0.80)
Obesity, no T2DM · n=17,604
FLOW 2024
Renal composite −24%
CKD + T2DM · n=3,533
STEP-1
Weight −14.9%
Semaglutide 2.4 mg · n=1,961
UK-authorised products — Ozempic · Wegovy · Rybelsus; indications and doses differ Use current NICE guidance and the product-specific UK SmPC; oral Wegovy is not currently NHS available
🔗
Dulaglutide
Trulicity · Eli Lilly · IgG4 Fc-fusion technology
✓ UK Licensed Generation III T2DM · REWIND CV data
Structure
2× GLP-1 analogue + IgG4 Fc fusion
Molecular weight
~60 kDa
Half-life
~5 days (112 hours)
Recycling mechanism
FcRn neonatal Fc receptor
Dosing
0.75→1.5→3→4.5 mg SC weekly
Max approved dose
4.5 mg (2020 extension)
Device
Single-use auto-injector pen
Immunogenicity
Very low (Fc modifications)
Fc-Fusion Half-Life Strategy
Dulaglutide uses a fundamentally different half-life extension strategy from albumin-binding agents. Two modified GLP-1(7-37) molecules are covalently linked via a short peptide connector to the Fc region of IgG4. The IgG4 Fc domain is modified (Leu²³⁴Ala, Leu²³⁵Ala) to eliminate Fc-gamma receptor binding and complement activation, minimising effector function and reducing immunogenicity. The large molecular size (~60 kDa) prevents glomerular filtration. Critically, neonatal Fc receptor (FcRn) recycling — the endosomal salvage mechanism that rescues IgG antibodies from lysosomal degradation — extends dulaglutide's half-life to ~5 days, far beyond what molecular size alone would predict.
REWIND — Broad CV Outcomes in Diverse T2DM Population
REWIND (2019, NEJM, n=9,901) demonstrated cardiovascular superiority of dulaglutide 1.5 mg weekly vs placebo (HR 0.88, 95% CI 0.79–0.99, p=0.026) in the most demographically broad GLP-1 RA outcomes trial — only 31% of participants had established CVD at baseline, making REWIND the most relevant to primary prevention. The primary MACE reduction of 12% was driven primarily by non-fatal stroke reduction (HR 0.76) — a finding that distinguishes REWIND from other GLP-1 RA trials. Dulaglutide also showed a renal composite benefit (HR 0.85), though less pronounced than semaglutide in FLOW.
REWIND
MACE −12% (HR 0.88)
69% primary prevention · n=9,901
AWARD-11
HbA1c −2.02% (4.5 mg)
Dose escalation trial · 2020
Licensed UK — T2DM (0.75–4.5 mg SC weekly) · REWIND CV superiority NICE NG28: alternative when semaglutide not tolerated or contraindicated
⛔
Albiglutide (Tanzeum / Eperzan) — Commercially Withdrawn 2018
Albiglutide (GSK) was a once-weekly GLP-1 RA utilising a different Fc-fusion strategy — GLP-1 fused to human albumin (not IgG4). Despite receiving FDA (2014) and EMA approval and demonstrating CV safety in HARMONY Outcomes (HR 0.78, p=0.0006 for superiority), GSK withdrew albiglutide from all markets in July 2018 for commercial reasons (poor market penetration vs Trulicity), not safety concerns. It is clinically notable that HARMONY Outcomes demonstrated CV superiority post-withdrawal, raising questions about the commercial decision. Albiglutide serves as a pharmacological reference point for albumin-fusion (as opposed to albumin-binding) half-life extension.
🔬
Efpeglenatide
Sanofi · Exendin-4 + IgG4 Fc + PEG · Phase 3 completed
FDA Approvable (Not yet filed UK) Generation III variant Exendin-4 + Fc hybrid
Structure
Exendin-4 + PEG + IgG4 Fc
Half-life
~10 days (longest peptide t½)
Dosing
4–6 mg SC once weekly
Status
Phase 3 complete · NDA not yet filed US
Efpeglenatide combines elements of both half-life extension strategies: exendin-4 (DPP-4-resistant peptide) conjugated to a PEGylated IgG4 Fc domain. The ~10-day half-life is the longest of any peptide GLP-1 RA. The AMPLITUDE-O trial (NEJM 2021, n=4,076) demonstrated MACE superiority (HR 0.73, p=0.0004) in a high-CV-risk T2DM population, establishing its outcomes credentials. However, Sanofi has not pursued regulatory filing in the US or EU, citing commercial strategy — making efpeglenatide a clinical orphan with strong evidence but no approved product.
Not licensed UK/US — Phase 3 complete — commercial development uncertain AMPLITUDE-O: MACE −27% · Strong evidence base · Regulatory filing not pursued
Generation IV

Dual GIP/GLP-1 Co-Agonists

Tirzepatide — dual incretin pharmacology · comparative trial evidence

Generation IV represents the most significant pharmacological advance since the introduction of GLP-1 RAs — the first agent designed as a single-molecule dual incretin co-agonist acting at both the GIP receptor and GLP-1 receptor simultaneously. This is mechanistically distinct from simply combining two separate agonists: tirzepatide is a single peptide optimised to activate both receptors with specific potency ratios and biased signalling characteristics that produce synergistic rather than additive effects.

🏆
Tirzepatide
Mounjaro (UK: T2DM and weight management) · Zepbound (US branding) · Eli Lilly
✓ UK Licensed — Mounjaro Generation IV — Dual GIP/GLP-1 Up to 22.5% weight loss NICE NG28 Feb 2026
Receptor targets
GIPR (full) + GLP-1R (partial)
GIP EC₅₀
~0.05 nM (full agonist)
GLP-1R activity
Biased · lower potency vs semaglutide
Half-life
~5 days (C20 fatty diacid)
T2DM dosing
2.5→5→10→15 mg SC weekly
HbA1c reduction
Up to −2.58% (15 mg)
Weight loss
Up to −22.5% (SURMOUNT-1, 15 mg)
NICE approval
NG28 Feb 2026 — T2DM criteria
Structural Innovation — Twin Incretin in a Single Peptide
Tirzepatide is a 39-amino-acid synthetic peptide based on the native GIP sequence with modifications that enable simultaneous high-affinity GIP receptor and GLP-1 receptor binding. Key structural features: (1) The GIP-based scaffold preserves high-affinity GIPR binding; (2) Amino acid substitutions at critical positions enable GLP-1R recognition — notably Aib² for DPP-4 resistance; (3) A C20 fatty diacid via γGlu-mini-PEG linker at Lys²⁶ achieves albumin binding sufficient for a ~5-day half-life. Unlike semaglutide (which is a biased Gs activator with strong β-arrestin recruitment), tirzepatide shows biased GLP-1R agonism favouring the Gs pathway over β-arrestin — potentially explaining its sustained weight loss efficacy without the receptor desensitisation seen with long-term full agonists.
SURPASS Programme — T2DM
The SURPASS trials (2021–2022) comprehensively established tirzepatide's superiority across comparators. SURPASS-2 (n=1,879, 40 weeks) compared tirzepatide vs semaglutide 1 mg: all three tirzepatide doses (5/10/15 mg) achieved superior HbA1c reduction (−1.86/−2.09/−2.37% vs −1.86% semaglutide) with 5, 8, and 11 kg greater weight loss respectively. SURPASS-CVOT (2024, n=13,000+) is the dedicated CV outcomes trial comparing tirzepatide vs dulaglutide, with published results (2025) confirming MACE non-inferiority of tirzepatide vs dulaglutide and demonstrating statistical superiority in the primary analysis — establishing tirzepatide as the first dual GIP/GLP-1 agonist with a positive dedicated CVOT.
SURMOUNT Programme — Obesity
SURMOUNT-1 (NEJM 2022, n=2,539, 72 weeks) in adults without T2DM: mean weight loss of −15.0%, −19.5%, −20.9% for 5, 10, 15 mg vs −3.1% placebo. Remarkably, 37% of participants on 15 mg achieved ≥25% weight loss — exceeding surgical benchmarks in a substantial proportion. SURMOUNT-2 (2023) in T2DM: −13.4% at 15 mg. SURMOUNT-3 (2023): combined with intensive lifestyle — mean −26.6% at 15 mg. SURMOUNT-4 (2024): withdrawal trial demonstrating weight regain on discontinuation, confirming the need for chronic therapy.
MASH / MASLD — FDA Approved Early 2026
The SYNERGY-NASH trial (2024, Lancet) demonstrated tirzepatide 10 and 15 mg resolved MASH (metabolic dysfunction-associated steatohepatitis) with no worsening fibrosis in 73.3% of participants at 52 weeks vs 10% placebo — the highest MASH resolution rate of any approved pharmacotherapy. FDA granted approval for MASH indication in early 2026 with breakthrough therapy designation, positioning tirzepatide as first-line pharmacotherapy for non-cirrhotic MASH with moderate-to-advanced fibrosis alongside resmetirom (Rezdiffra). This represents tirzepatide's expansion from metabolic to hepatic disease.
Obstructive Sleep Apnea (OSA) — Emerging Indication
SURMOUNT-OSA Phase 3 trial demonstrated tirzepatide reduced apnea-hypopnea index (AHI) by 25.3 to 29.3 events per hour vs approximately 5 events/hour with placebo, alongside 17–20% body weight reduction. These outcomes position tirzepatide as the first pharmacological therapy with clinically meaningful efficacy in moderate-to-severe OSA, a condition affecting >900 million adults globally with few non-surgical interventions. Regulatory submissions anticipated 2026.
SURPASS-2
HbA1c −2.37% (15 mg)
Superior to sema 1mg · n=1,879
SURMOUNT-1
Weight −20.9% (15 mg)
No T2DM · n=2,539 · 72 weeks
SYNERGY-NASH
MASH resolution 62–74%
Lancet 2024 · vs 10% placebo
SURMOUNT-3
Weight −26.6% (lifestyle+)
Intensive lifestyle combo · 2023
Mounjaro is UK-authorised for T2DM and weight management NICE NG28 covers T2DM pathways; NICE TA1026 covers eligible adults with overweight or obesity
Combination Class

Fixed-Ratio Insulin Combinations

IDegLira · IGlarLixi · Co-formulated basal insulin + GLP-1 RA

Fixed-ratio combination products co-formulate a basal insulin with a GLP-1 RA in a single pen device, administered as a single daily injection. They are designed to provide complementary glycaemic mechanisms — basal insulin addresses fasting hyperglycaemia while the GLP-1 RA reduces postprandial excursions and attenuates insulin-related weight gain — with simplified injection burden compared with separate titration of each agent.

⚡
IDegLira
Xultophy · Insulin degludec 100 U/mL + liraglutide 3.6 mg/mL · Novo Nordisk
✓ UK Licensed Basal insulin + GLP-1 RA
Components
Degludec + Liraglutide
Ratio
1 unit degludec : 0.036 mg liraglutide
Dose range
10–50 dose steps OD
Max liraglutide
1.8 mg/day (at max dose)
IDegLira delivers both components at a fixed 1:0.036 ratio, allowing simple titration by dose steps. The DUAL programme demonstrated HbA1c reduction of ~1.9% from baseline in insulin-naive patients, with weight-neutral to weight-losing outcomes (unlike basal insulin alone). The GLP-1 RA component attenuates the hypoglycaemia-promoting effects of intensifying insulin and prevents the weight gain typically seen with insulin titration — addressing two major barriers to insulin intensification. Key limitation: the fixed ratio means the GLP-1 RA dose cannot be independently titrated, potentially limiting dose flexibility.
DUAL-I
HbA1c −1.9%
Insulin-naive · 26 weeks
DUAL-VII
Weight neutral vs IDeg alone
Insulin intensification
Licensed UK — T2DM · SC once daily
⚡
IGlarLixi
Suliqua · Insulin glargine 100 U/mL + lixisenatide 33 mcg/mL · Sanofi
✓ UK Licensed Basal insulin + GLP-1 RA
Components
Glargine U100 + Lixisenatide
Pen A (10–40 U)
Glargine 1U : Lixisenatide 1mcg
Pen B (30–60 U)
Glargine 1U : Lixisenatide 0.5mcg
Timing
SC OD within 1 hour before meal
IGlarLixi differs from IDegLira in utilising lixisenatide — the short-acting exendin-4 analogue with the most pronounced gastric emptying delay. The LixiLan programme demonstrated superiority to glargine alone (HbA1c −1.6% vs −1.3%) with significantly less weight gain. Two pen strengths allow flexibility across the insulin dose range. Key advantage over IDegLira: lixisenatide's strong postprandial action specifically addresses mealtime hyperglycaemia, complementing glargine's fasting glucose control in a pharmacokinetically rational pairing.
LixiLan-O
HbA1c −1.6% vs −1.3% glargine
Insulin-naive · 30 weeks
Licensed UK — T2DM · Pen A and Pen B
Oral Class

Oral GLP-1 Receptor Agonists

Peptide-based (SNAC) and non-peptide small-molecule approaches

The oral delivery of GLP-1 RAs represents the most commercially significant challenge in incretin pharmacology. Two distinct approaches have now reached regulatory approval: oral peptide delivery (semaglutide enabled by SNAC absorption technology, licensed 2019) and oral non-peptide small-molecule GLP-1 RAs (orforglipron/Foundayo FDA approved April 2026, danuglipron in Phase 3). Small-molecule agents do not require absorption enhancers, have no food interaction constraints, are manufacturable without recombinant biology, and could transform access economics in low-income settings. Orforglipron's approval marks a watershed moment — the first small-molecule GLP-1 RA, enabling true generic development rather than biosimilars.

💡
Why Small-Molecule GLP-1 RAs Are a Paradigm Shift
GLP-1R is a class B GPCR historically considered undruggable by small molecules due to its large extracellular peptide-binding domain. The recent cryo-EM structures of GLP-1R in active conformations revealed a previously unknown transmembrane allosteric site — a lipid-facing pocket within the transmembrane bundle distinct from the orthosteric peptide-binding site. Orforglipron, danuglipron, and lotiglipron are all non-peptide small molecules that bind this transmembrane allosteric site, acting as positive allosteric modulators with agonist activity — achieving GLP-1R activation without requiring the large peptide scaffold that makes parenteral delivery necessary.
✓
Orforglipron (Foundayo)
LY3502970 · Eli Lilly · Non-peptide oral GLP-1 RA · Once daily tablet
✓ FDA APPROVED — April 1, 2026
Brand name
Foundayo (US)
Structure
Small molecule · Non-peptide
Mechanism
TM allosteric GLP-1R agonist
Dosing
Oral once daily · No food/water restriction
FDA approval
April 1, 2026 (ahead of PDUFA date)
Indication
Chronic weight management (obesity/overweight)
Weight loss
−12.6% at highest dose (Phase 2, 26 wks)
Key innovation
First GLP-1 pill with no timing restrictions
Orforglipron (brand name Foundayo) received FDA approval on April 1, 2026, becoming the first small-molecule GLP-1 receptor agonist approved for chronic weight management. Unlike oral semaglutide (Rybelsus), orforglipron has no food or water restrictions and can be taken at any time of day, addressing the principal adherence limitation of SNAC-formulated peptides. Phase 2 data (NEJM Evidence 2023; ATTAIN trials 2025) demonstrated dose-dependent HbA1c reduction (−1.4 to −2.1%) and weight loss (−7.9 to −12.6%) over 26 weeks in T2DM, with ATTAIN-2 showing 10.5% weight loss and HbA1c reduction of 1.8%. As a small-molecule agent (not a peptide), orforglipron is manufacturable without recombinant biology, enabling significantly lower manufacturing costs and the potential for true generic entry (not biosimilars), which could transform global access in low-income settings. The ACHIEVE obesity trials demonstrated 7–10% body weight reduction over 36 weeks, with 11% weight loss at highest dose at 72 weeks. UK/EU regulatory filing status pending.
💊
Danuglipron
PF-06882961 · Pfizer · Oral non-peptide GLP-1 RA · Twice daily (IR) / OD (XR)
Phase 2b — partial discontinuation
Structure
Non-peptide small molecule
Phase 2b
−7.7% weight (40 mg BID)
GI tolerability
Higher vs orforglipron Phase 2
Status 2024
Pfizer paused obesity programme
Danuglipron (Pfizer) demonstrated weight loss of −6.9 to −11.7% across doses in Phase 2b. However, Pfizer announced in December 2023 that it was discontinuing the danuglipron twice-daily IR programme for obesity due to GI tolerability signals and a liver enzyme elevation signal requiring further investigation, while continuing development of an extended-release once-daily formulation for T2DM. As of 2025, the once-daily XR formulation remains in development, with a Phase 2b obesity study ongoing. The liver signal remains under regulatory scrutiny.
💊
Lotiglipron
PF-07081532 · Pfizer · Alternative non-peptide oral GLP-1 RA
Discontinued — liver signal 2023
Lotiglipron (Pfizer) was discontinued in June 2023 after Phase 2 data revealed clinically significant hepatotoxicity signals — elevated liver enzymes (ALT/AST) in a substantial proportion of participants. This led to complete programme termination. The compound's hepatic safety profile contrasts with orforglipron, which has not demonstrated comparable liver signals in Phase 2 data, suggesting this may be a compound-specific rather than class-wide concern. Lotiglipron's discontinuation heightened regulatory scrutiny of hepatic monitoring requirements across the oral non-peptide class.
📌
Subcutaneous Semaglutide Implant
OW-030 · Novo Nordisk · 6-month implant — once-every-6-months dosing
Phase 2
Delivery
SC implant · biannual insertion
Duration
~6 months sustained release
Rationale
Eliminates weekly injection burden
Status
Phase 2 · Results expected 2025
A 6-month implantable semaglutide delivery system under development by Novo Nordisk — a biodegradable polymer matrix inserted subcutaneously via a small trocar, releasing semaglutide continuously over 6 months. Designed to eliminate the weekly injection requirement and address adherence loss due to injection fatigue, particularly in patients requiring very long-term therapy. The concept parallels hormonal implants (Nexplanon) and long-acting antiretroviral implants (cabotegravir). Phase 2 efficacy and tolerability data expected 2025–2026.
Generation V

Triple Agonists — GIP + GLP-1 + Glucagon

Retatrutide · Mazdutide · Adding energy expenditure to dual incretin signalling

The third receptor target — the glucagon receptor (GCGR) — adds a fundamentally new mechanism to the dual incretin framework. Glucagon stimulates hepatic gluconeogenesis (raising glucose) but simultaneously increases energy expenditure through brown adipose tissue thermogenesis, hepatic fatty acid oxidation, and lipolysis. In isolation, glucagon receptor agonism causes hyperglycaemia — making it pharmacologically incompatible with metabolic disease treatment. But combined with GLP-1R agonism (which powerfully suppresses glucose elevation and insulin-independent glucose disposal), the hyperglycaemic effect of glucagon is neutralised while its energy-expenditure-promoting effects are retained — a pharmacologically elegant co-dependency.

🔥
Retatrutide
LY3437943 · Eli Lilly · GIP + GLP-1 + Glucagon receptor triple agonist
Phase 3 — TRIUMPH programme
Targets
GIPR + GLP-1R + GCGR
Phase 2 weight loss
−24.2% at 48 weeks (12 mg)
HbA1c reduction
−2.2% (T2DM Phase 2)
Half-life
~6 days · weekly dosing
Dosing (Phase 3)
4, 8, 12 mg SC weekly
Expected approval
2026–2027 (US) · EU/UK TBC
Retatrutide's Phase 2 obesity data (NEJM 2023, n=338, 48 weeks) produced the highest pharmacologically-mediated weight loss reported in any clinical trial to that date: mean −24.2% body weight at 12 mg, with 26% of participants losing ≥30% of body weight. This substantially exceeds tirzepatide's Phase 3 data (~20.9%) and approaches Roux-en-Y gastric bypass outcomes (~25–30%). The mechanism is additive synergy: GCGR activation increases hepatic fatty acid oxidation and brown adipose tissue thermogenesis beyond what GIP+GLP-1 dual agonism achieves alone. The TRIUMPH Phase 3 programme (2024–2026) is evaluating retatrutide in obesity, T2DM, and cardiovascular outcomes.
🧪
Mazdutide
IBI362 · Innovent Biologics / Eli Lilly (Asia) · GLP-1R + GCGR dual agonist
Phase 3 — China (GLORY programme)
Targets
GLP-1R + GCGR (no GIP)
Weight loss
−15.2% at 24 weeks (6 mg)
Region
China-based trials · Pan-Asia
Status
Phase 3 · NMPA filing 2025
Mazdutide is a GLP-1R/GCGR dual agonist without GIP receptor activity, representing an intermediate pharmacological position between selective GLP-1 RAs and triple agonists. It demonstrates that the addition of GCGR agonism to GLP-1R alone (without GIPR) produces meaningfully greater weight loss (~15% at 24 weeks) than selective GLP-1 RAs at comparable timescales. Phase 3 GLORY programme data from China expected 2025, with potential NMPA approval and limited global licensing. Primarily of pharmacological interest for defining the independent contribution of glucagon receptor agonism to weight loss beyond GLP-1 effects.
💪
Pemvidutide
ALT-801 · Altimmune · GLP-1R / GCGR dual agonist with muscle-sparing profile
Phase 2b — IMPACT trial
Targets
GLP-1R + GCGR
Key differentiator
Fat-preferential loss · Lean mass preserved
Phase 2 weight
−15.6% at 48 weeks
Lean mass loss
~22% vs ~38–40% with sema
Pemvidutide's most distinctive characteristic is its apparently preferential fat mass reduction with relative preservation of lean body mass. In Phase 2 data (NEJM Evidence 2024), pemvidutide produced −15.6% total weight loss at 48 weeks, but fat mass accounted for a greater proportion of loss compared with semaglutide or tirzepatide — where lean mass loss of 38–40% of total weight loss is observed. The mechanism may relate to glucagon receptor-mediated effects on protein metabolism and hepatic amino acid handling. Muscle preservation is the key clinical question in weight management pharmacotherapy, particularly as obesity medicines are used in older, sarcopenic patients. Phase 2b IMPACT trial ongoing 2025.
Emerging Class

Novel Mechanisms & Combination Strategies

GLP-1/amylin · GLP-1/FGF21 · GLP-1/GIP/Amylin · Brain-biased agonism · 2025–2030 horizon

🌊
CagriSema (Cagrilintide + Semaglutide)
Novo Nordisk · GLP-1 RA + long-acting amylin analogue · Once weekly co-injection
Phase 3 — REDEFINE programme
Components
Semaglutide 2.4 mg + Cagrilintide 2.4 mg
Amylin target
Area postrema · NTS satiety centres
Phase 2 weight
−17.1% at 32 weeks (combo)
REDEFINE-1 result
−22.7% at 68 weeks (2024)
Expected filing
NDA/MAA 2025–2026
Administration
Co-injection (separate pens → combo pen)
Amylin is a pancreatic beta-cell hormone co-secreted with insulin, acting on area postrema and NTS receptors to produce satiety, reduce food intake, and slow gastric emptying — complementary but mechanistically distinct from GLP-1R pathways. Cagrilintide is a long-acting amylin analogue (t½ ~7 days) designed for once-weekly co-administration with semaglutide 2.4 mg. The REDEFINE-1 trial (2024, n=3,400, 68 weeks) reported mean weight loss of −22.7% vs −8.1% placebo — matching or exceeding tirzepatide's SURMOUNT-1 benchmark. CagriSema positions Novo Nordisk competitively against Eli Lilly's tirzepatide and retatrutide pipeline. Regulatory filing anticipated 2025–2026.
🧬
Amycretin
NN9487 · Novo Nordisk · Single-molecule GLP-1R + amylin receptor co-agonist · Oral & SC
Phase 2 — Oral & SC
Innovation
Single molecule GLP-1R/amylin dual
Oral Phase 1
−13.1% weight at 12 weeks
SC Phase 1
−22% estimated 36 weeks
Status
Phase 2 · 2025 results
Amycretin fuses GLP-1R and amylin receptor agonism into a single peptide molecule — a more elegant approach than CagriSema's two-drug co-injection strategy. The oral amycretin Phase 1 data (Lancet 2024) was remarkable: −13.1% weight loss at 12 weeks — faster than any previously reported oral agent and comparable to early SC data — from a single molecule without SNAC absorption enhancer. If confirmed in Phase 2, amycretin could represent Novo Nordisk's next-generation platform beyond semaglutide, combining the convenience of oral delivery with the mechanism of GLP-1/amylin combination.
🔬
Survodutide
BI 456906 · Boehringer Ingelheim / Zealand Pharma · GLP-1R + GCGR dual agonist · MASH focus
Phase 3 — MASH/obesity
Targets
GLP-1R + GCGR
Key focus
MASH/NAFLD · liver histology
Weight (Phase 2)
−14.9% at 46 weeks
MASH response
83% fibrosis improvement (Phase 2)
Survodutide is strategically positioned primarily for MASH/MASLD — a hepatic indication where glucagon receptor agonism's direct hepatic effects (promoting fatty acid oxidation, reducing hepatic steatosis) may add meaningfully to GLP-1R-mediated weight loss. Phase 2 liver biopsy data showed MASH resolution in 47% and fibrosis improvement in 83% of participants — striking liver-specific benefits. Phase 3 MASH outcomes trial ongoing with Boehringer Ingelheim/Zealand Pharma. Positions as a direct competitor to tirzepatide (SYNERGY-NASH) and resmetirom in the rapidly expanding MASH treatment space.
🔭
GLP-1R / FGF21 Co-Agonists
Multiple programmes · Semaglutide-FGF21 bispecific · LLF580 · BIO89-100 class
Phase 1–2 · 2025–2027
FGF21 effects
Adiponectin ↑ · Hepatic lipid ↓ · TG ↓
Rationale
Complementary metabolic + liver effects
Key programmes
Novo (sema-FGF21 bispecific) · 89bio
Target conditions
MASH · T2DM · Obesity · ASCVD
Fibroblast growth factor 21 (FGF21) is a hepatokine that increases adiponectin secretion, promotes fatty acid oxidation, reduces triglycerides, and improves insulin sensitivity through mechanisms distinct from GLP-1R signalling. GLP-1R/FGF21 bispecific conjugates or co-formulated therapies aim to combine GLP-1-mediated appetite suppression and insulin secretion with FGF21's lipid-lowering, liver-protective, and adiponectin-enhancing effects. Novo Nordisk disclosed a semaglutide-FGF21 bispecific programme in 2024. 89bio's pegozafermin (FGF21 analogue) is separately in Phase 3 for MASH, and combination strategies with GLP-1 RAs are anticipated. This class is particularly compelling for the MASH + dyslipidaemia + obesity triad.
🧠
CNS-Biased / Tissue-Selective GLP-1 RAs
Brain-penetrant variants · Peripheral-restricted variants · Next-generation differentiation
Preclinical – Phase 1 · 2026+
Concept
Tissue-biased GLP-1R agonism
CNS-biased goal
Greater appetite suppression · Less GI SE
Peripheral-restricted
GI SE reduction · Insulin action focus
Programmes
Multiple academic + industry · 2026–2030
The primary adverse effects of current GLP-1 RAs — nausea, vomiting, constipation — arise predominantly from GLP-1R activation in the gut and brainstem area postrema. Peripherally-restricted GLP-1 RAs (poor CNS penetration) could potentially reduce GI side effects while preserving pancreatic and peripheral metabolic effects. Conversely, CNS-penetrant / brain-biased variants aim to maximise hypothalamic appetite suppression while minimising peripheral GI activation. Additionally, β-arrestin-biased GLP-1 RAs that preferentially engage Gs over β-arrestin at GLP-1R are being developed to reduce receptor desensitisation during chronic therapy — potentially maintaining efficacy beyond the ~18-month plateau observed with current agents. These represent the frontier of precision pharmacology for incretin therapy.
Horizon

The Future Landscape — 2026–2030

Projected approvals · Combination pharmacology · Delivery innovation · Biosimilars

The GLP-1 RA therapeutic landscape is undergoing the most rapid period of pharmacological innovation since insulin's introduction. By 2030, the therapeutic class is expected to encompass agents addressing mechanisms far beyond glycaemia and weight, with implications for heart failure, neurodegenerative disease, addiction, and — through biosimilar entry — global access transformation.

Projected Approvals Timeline (2025–2030)
AgentClassCompanyIndicationExpectedStatus
Orforglipron Oral non-peptide GLP-1 RA Eli Lilly T2DM + Obesity 2025–2026 Phase 3
CagriSema GLP-1 + Amylin Novo Nordisk Obesity 2026 Phase 3
Retatrutide Triple GIP/GLP-1/GCG Eli Lilly Obesity + T2DM 2026–2027 Phase 3
Tirzepatide (obesity) Dual GIP/GLP-1 Eli Lilly Weight management (Mounjaro UK) Authorised 2023 UK authorised
Amycretin (SC) GLP-1 + Amylin (single molecule) Novo Nordisk Obesity 2027 Phase 2
Semaglutide implant 6-month depot GLP-1 RA Novo Nordisk T2DM + Obesity 2027–2028 Phase 2
GLP-1/FGF21 bispecific GLP-1 + FGF21 Novo Nordisk / others MASH + Obesity 2028+ Phase 1–2
Semaglutide biosimilar Biosimilar GLP-1 RA Multiple (Mylan, Sun, Biocon) T2DM / Obesity 2028–2030 Development
Expanding Indications Beyond Cardiometabolic Disease

The GLP-1 receptor is expressed broadly across tissues with implications beyond metabolic disease. Several expanding indications are supported by emerging evidence:

🔭
Heart Failure — STEP-HFpEF
STEP-HFpEF (NEJM 2023, n=529) demonstrated semaglutide 2.4 mg significantly improved KCCQ-CSS scores (quality of life), 6-minute walk distance, and CRP (inflammation marker) in patients with HFpEF and obesity, without worsening renal function. A dedicated HFpEF outcomes trial is now enrolling. GLP-1 RA therapy in HFpEF may act through multiple mechanisms: weight loss (reducing ventricular preload), anti-inflammatory effects, and direct myocardial GLP-1R signalling improving diastolic function.
🧠
Neurodegeneration — Parkinson's & Alzheimer's Disease
GLP-1R is expressed in substantia nigra dopaminergic neurons and hippocampal regions. Epidemiological data show reduced Parkinson's disease incidence in GLP-1 RA-treated T2DM patients. The SPARK trial (liraglutide, UCL, 2024) demonstrated significant slowing of Parkinson's disease progression on dopaminergic imaging over 12 months vs placebo — the most encouraging disease-modifying result in Parkinson's pharmacology in two decades. Semaglutide trials in MCI/Alzheimer's (EVOKE, EVOKE+, n=1,840) have Phase 3 data expected 2025 — with observational data from real-world T2DM cohorts suggesting 40–70% lower dementia incidence in semaglutide-treated patients.
🍺
Addiction & Reward Behaviour
GLP-1R is expressed in the ventral tegmental area (VTA) and nucleus accumbens — mesolimbic reward circuitry. Preclinical models show GLP-1 RA suppression of alcohol preference, nicotine seeking, and opioid reward. Phase 2 trials of semaglutide in alcohol use disorder (NCT05520398, n=48) and nicotine dependence are ongoing, with early signals of reduced consumption. The observation that GLP-1 RA users report reduced craving for alcohol, tobacco, and recreational drugs — noted in real-world pharmacovigilance — has generated substantial academic and commercial interest in addiction medicine applications.
💊
Biosimilar Entry — The Access Transformation
Semaglutide's composition-of-matter patents expire in the UK in 2031 (earlier in some markets). Biosimilar development (Mylan/Viatris, Biocon, Sun Pharma, and multiple Chinese manufacturers) is underway — with projected cost reductions of 60–80% on biosimilar entry, analogous to the insulin biosimilar market. If oral non-peptide GLP-1 RAs (orforglipron, danuglipron) gain approval, their small-molecule nature allows generic rather than biosimilar development — potentially reducing cost by 90%+ and transforming access in LMICs where the global burden of T2DM and obesity is highest. The WHO is actively evaluating GLP-1 RA access strategies for their Essential Medicines List.
Reference

Full Comparison Table

All licensed and late-stage agents — side by side

Drug Class Route Frequency t½ HbA1c↓ Weight↓ CV Trial UK Status
Exenatide IR Exendin-4 SC Twice daily 2.4 h 0.8–1.5% ~2–3 kg EXSCEL (neutral) Licensed
Exenatide XR Exendin-4 + PLGA SC Weekly ~2 wks 1.3–1.9% ~3 kg EXSCEL (neutral) Licensed
Lixisenatide Exendin-4 modified SC Once daily 3 h 0.8–1.0% ~2 kg ELIXA (neutral) Licensed
Liraglutide Human GLP-1 + C16 SC Once daily 13 h 1.0–1.6% ~5–6 kg LEADER ✓ (−13%) Licensed
Dulaglutide GLP-1 × IgG4 Fc SC Weekly 5 d 1.1–2.0% ~4–6 kg REWIND ✓ (−12%) Licensed
Semaglutide SC Human GLP-1 + C18 SC Weekly 7 d 1.5–1.8% 10–15% SELECT ✓ (−20%) Licensed ★
Semaglutide oral Human GLP-1 + SNAC Oral Once daily 7 d 0.9–1.4% ~5 kg PIONEER 6 (neutral) Licensed
Tirzepatide GIP + GLP-1 dual SC Weekly 5 d 2.0–2.6% 15–22% SURPASS-CVOT Licensed (T2DM + Obesity)
CagriSema GLP-1 + Amylin SC Weekly 7 d TBC ~23% Phase 3 ongoing Phase 3
Retatrutide GIP + GLP-1 + GCG SC Weekly 6 d ~2.2% ~24% TRIUMPH (Phase 3) Phase 3
Orforglipron Non-peptide oral GLP-1 RA Oral Once daily ~12 h 1.4–2.1% ~9–13% ATTAIN (Phase 3) Phase 3
Amycretin GLP-1 + Amylin (single mol.) Oral / SC Weekly TBC TBC ~22%+ Phase 2 Phase 2
Albiglutide GLP-1 × HSA fusion SC Weekly 5 d 0.7–1.0% ~1 kg HARMONY ✓ (−22%) Withdrawn 2018

Data are summaries of published trials and regulatory sources and are not a prescribing ranking. HbA1c and weight changes vary by dose, comparator and population. CV trial outcomes marked ✓ indicate statistical superiority for the stated endpoint and comparator only. Approval status must be checked against the current MHRA product record. CV = cardiovascular; MACE = major adverse cardiovascular events; TBC = to be confirmed.